Kexing Biopharm (688136.SH): Ophthalmic Formulation GB10 Injection Receives Clinical Trial Approval

Stock News2025-12-08

Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The NMPA has approved Shenzhen Kexing to conduct clinical trials for "GB10 Injection."

GB10 Injection is an anti-VEGF/Ang-2 dual-target antibody high-concentration ophthalmic protein drug formulation independently developed by Shenzhen Kexing with global intellectual property rights. With a concentration of 140mg/mL, GB10 Injection can reduce injection volume or increase dosage while extending the dosing interval, potentially enabling administration once every four months—significantly improving patient compliance.

Preclinical data indicate that its biological activity and animal efficacy meet international benchmark levels. In laser-induced monkey CNV (choroidal neovascularization) efficacy models, it effectively inhibits abnormal blood vessel growth in the retina.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128782685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128782685","market":"fut","top_or_hot":-1,"title":"Kexing Biopharm (688136.SH): Ophthalmic Formulation GB10 Injection Receives Clinical Trial Approval","media":"Stock News","content":"<p>Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The NMPA has approved Shenzhen Kexing to conduct clinical trials for \"GB10 Injection.\"</p>\n<p>GB10 Injection is an anti-VEGF/Ang-2 dual-target antibody high-concentration ophthalmic protein drug formulation independently developed by Shenzhen Kexing with global intellectual property rights. With a concentration of 140mg/mL, GB10 Injection can reduce injection volume or increase dosage while extending the dosing interval, potentially enabling administration once every four months—significantly improving patient compliance.</p>\n<p>Preclinical data indicate that its biological activity and animal efficacy meet international benchmark levels. In laser-induced monkey CNV (choroidal neovascularization) efficacy models, it effectively inhibits abnormal blood vessel growth in the retina.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kexing Biopharm (688136.SH): Ophthalmic Formulation GB10 Injection Receives Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKexing Biopharm (688136.SH): Ophthalmic Formulation GB10 Injection Receives Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The NMPA has approved Shenzhen Kexing to conduct clinical trials for \"GB10 Injection.\"</p>\n<p>GB10 Injection is an anti-VEGF/Ang-2 dual-target antibody high-concentration ophthalmic protein drug formulation independently developed by Shenzhen Kexing with global intellectual property rights. With a concentration of 140mg/mL, GB10 Injection can reduce injection volume or increase dosage while extending the dosing interval, potentially enabling administration once every four months—significantly improving patient compliance.</p>\n<p>Preclinical data indicate that its biological activity and animal efficacy meet international benchmark levels. In laser-induced monkey CNV (choroidal neovascularization) efficacy models, it effectively inhibits abnormal blood vessel growth in the retina.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688136","symbol_name":"科兴制药","start_time":0,"source_url":"","article_id":"1128782685","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128782685","pubTimestamp":1765191621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), recently received the \"Drug Clinical Trial Approval...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK0239":"医药制造"},"translate_title":"科兴生物（688136.SH）：眼用制剂GB10注射液获临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":1},"content_text":"Kexing Biopharm Co.,Ltd. (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. (\"Shenzhen Kexing\"), recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA). The NMPA has approved Shenzhen Kexing to conduct clinical trials for \"GB10 Injection.\"\nGB10 Injection is an anti-VEGF/Ang-2 dual-target antibody high-concentration ophthalmic protein drug formulation independently developed by Shenzhen Kexing with global intellectual property rights. With a concentration of 140mg/mL, GB10 Injection can reduce injection volume or increase dosage while extending the dosing interval, potentially enabling administration once every four months—significantly improving patient compliance.\nPreclinical data indicate that its biological activity and animal efficacy meet international benchmark levels. In laser-induced monkey CNV (choroidal neovascularization) efficacy models, it effectively inhibits abnormal blood vessel growth in the retina.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128782685","isCrawlerRequest":true}